The Consortium of Multiple Sclerosis Centers

Registration is Open for Leading MS Educational Conference for Healthcare Professionals, May 31–June 3, Aurora, CO

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

Contact: Annie Scully, annie.scully@mscare.org, 201-310-9252 MS TeamWorks Inspirational Videos for the Multiple Sclerosis Community Reaches Viewer Milestone Video Series Featuring Diverse Voices of MS Hope and Insight Records More than 200,000 Views

Scott Newsome, DO, and Ellen Mowry, MD, discuss the ongoing TREAT-MS trial and its goals, the importance of the findings for clinical practice in multiple sclerosis, and the ongoing discussion around induction vs escalation in MS treatment. [WATCH TIME: 24 minutes]

The senior vice president for research and training at the Kessler Foundation discussed the assessment of cognitive challenges among patients with multiple sclerosis and planning for treatment options when necessary. [WATCH TIME: 4 minutes]

The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Robert Fox, MD, who presented the DISCO-MS study results at the CMSC 2022 Annual Meeting, offered his closing thoughts on the data and the take-home messaging for clinicians.

Robert Fox, MD, offered perspective on data from the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis and how it compares with day-to-day clinical practice.

Robert Fox, MD, shared the details of the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis, presented at the CMSC 2022 Annual Meeting.

Daniel Kantor, MD, discussed the data from his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis, and what questions are still lingering among the clinical community.

Daniel Kantor, MD, discussed his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis who are being treated with sphingosine 1 phosphate receptor modulators.

Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.

Jeffrey Cohen, MD, shared his perspective on the current use and study of stem cells for the treatment of multiple sclerosis, which he covered in the CMSC Presidential Lecture at the 2022 annual meeting.

The postdoctoral researcher at the Johns Hopkins Multiple Sclerosis Center shared his perspective on the use of spinal cord atrophy in clinical practice to measure disease progression in MS and how it might become more accessible. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Riley Bove, MD; Blake E. Dewey, PhD; Bruce Cree, MD, PhD, MAS; John DeLuca, PhD; Shuvro Roy, MD; and Tanuja Chitnis, MD. [LISTEN TIME: 26 minutes]

The online tool was evaluated in a cohort of 501 patients and healthcare providers, showing positive trends in 9 of 11 outcomes assessed. Notably, disease-modifying therapy start, adherence, and long-term mental health were all improved in the intervention group.

The associate professor of neurology at UCSF Weill Institute for Neurosciences discussed the findings of a social media listening study that suggested women with multiple sclerosis used social media platforms to discuss treatment during and around pregnancy. [WATCH TIME: 4 minutes]

The form, which is freely available through the Epic and Cerner EHR platforms, was developed to streamline and standardize patient data collection to allow clinicians more time with patients and more consistent information.

Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.

June Halper, MSN, APC-C, MSCN, FAAN, the chief executive officer of the Consortium of Multiple Sclerosis Centers, shared her perspective on what to expect from this year’s annual meeting, which takes place June 1-4, 2022, in National Harbor, Maryland.

Alberto Ascherio, MD, DrPH, and Lawrence Steinman, MD, join NeurologyLive in a conversation about the clinical and research implications of a causative relationship between Epstein-Barr virus and multiple sclerosis.

An expert-led panel discuss the implications of recent findings that suggest a causative relationship between infection with Epstein-Barr virus and development of multiple sclerosis.

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed the importance of continued research on how patients with multiple sclerosis experience cognitive decline as they age.

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 3 minutes]

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided insight on a new study that looks at the connection between brain structure and cognitive decline in patients with multiple sclerosis and other neurodegenerative disorders.